Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Buy
64
RVTY Quote, Financials, Valuation and Earnings
Last price:
$111.83
Seasonality move
:
2.24%
Day range:
$110.68 - $112.39
52-week range:
$97.32 - $129.50
Dividend yield:
0.25%
P/E ratio:
50.64x
P/S ratio:
4.99x
P/B ratio:
1.75x
Volume:
752.8K
Avg. volume:
1M
1-year change:
6.7%
Market cap:
$13.5B
Revenue:
$2.8B
EPS (TTM):
$2.21
Analysts' Opinion
-
Consensus RatingRevvity has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $141.19, Revvity has an estimated upside of 26.17% from its current price of $111.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $120.00 representing 100% downside risk from its current price of $111.91.
Fair Value
-
According to the consensus of 15 analysts, Revvity has 26.17% upside to fair value with a price target of $141.19 per share.
RVTY vs. S&P 500
-
Over the past 5 trading days, Revvity has underperformed the S&P 500 by -0.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Revvity does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Revvity has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Revvity reported revenues of $729.4M.
Earnings Growth
-
Revvity has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Revvity reported earnings per share of $0.78.
Enterprise value:
15.4B
EV / Invested capital:
1.43x
Price / LTM sales:
4.99x
EV / EBIT:
37.43x
EV / Revenue:
5.60x
PEG ratio (5yr expected):
--
EV / Free cash flow:
28.50x
Price / Operating cash flow:
25.39x
Enterprise value / EBITDA:
18.37x
Gross Profit (TTM):
$1.5B
Return On Assets:
2.06%
Net Income Margin (TTM):
9.81%
Return On Equity:
3.45%
Return On Invested Capital:
2.37%
Operating Margin:
17.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $3.3B | $2.8B | $2.8B | $695.9M | $729.4M | |
| Gross Profit | $2B | $1.5B | $1.5B | $383.5M | $412.3M | |
| Operating Income | $745.3M | $300.6M | $346.7M | $82.1M | $124.5M | |
| EBITDA | $1.2B | $713.6M | $840.3M | $161.5M | $222.4M | |
| Diluted EPS | $4.58 | $5.50 | $2.21 | $0.64 | $0.78 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.4B | $3.3B | $3B | $2.3B | |
| Total Assets | $8B | $15B | $14.1B | $13.6B | $12.4B | |
| Current Liabilities | $1.7B | $1.2B | $1.5B | $1.5B | $653.1M | |
| Total Liabilities | $4.2B | $7.9B | $6.7B | $5.7B | $4.7B | |
| Total Equity | $3.7B | $7.1B | $7.4B | $7.9B | $7.7B | |
| Total Debt | $2B | $5B | $4.4B | $3.9B | $3.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $679.8M | $91.3M | $628.3M | $196.6M | $174.2M | |
| Cash From Investing | -$132.9M | $1.3B | $776.2M | -$414.8M | -$17.3M | |
| Cash From Financing | -$661.8M | -$947.1M | -$1.1B | -$19.6M | -$193M | |
| Free Cash Flow | $594.2M | $9.9M | $541.7M | $172.5M | $149.8M | |
RVTY
Sector
Market Cap
$13.5B
$38.4M
Price % of 52-Week High
86.42%
45.53%
Dividend Yield
0.25%
0%
Shareholder Yield
4.08%
-0.78%
1-Year Price Total Return
6.7%
-39.05%
Beta (5-Year)
1.064
0.774
Dividend yield:
0.25%
Annualized payout:
$0.28
Payout ratio:
12.74%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$112.30
200-day SMA
Sell
Level
$116.28
Bollinger Bands (100)
Sell
Level
112.01 - 121.37
Chaikin Money Flow
Buy
Level
248.9M
20-day SMA
Sell
Level
$112.69
Relative Strength Index (RSI14)
Sell
Level
45.22
ADX Line
Sell
Level
18.86
Williams %R
Neutral
Level
-61.5385
50-day SMA
Sell
Level
$116.62
MACD (12, 26)
Sell
Level
-1.46
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
191.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8664)
Buy
CA Score
(Annual)
Level (0.2138)
Buy
Beneish M-Score
(Annual)
Level (-2.5568)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.7721)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Stock Forecast FAQ
In the current month, RVTY has received 8 Buy ratings 7 Hold ratings, and 0 Sell ratings. The RVTY average analyst price target in the past 3 months is $141.19.
-
Where Will Revvity Stock Be In 1 Year?
According to analysts, the consensus estimate is that Revvity share price will rise to $141.19 per share over the next 12 months.
-
What Do Analysts Say About Revvity?
Analysts are divided on their view about Revvity share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revvity is a Sell and believe this share price will drop from its current level to $120.00.
-
What Is Revvity's Price Target?
The price target for Revvity over the next 1-year time period is forecast to be $141.19 according to 15 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is RVTY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Revvity is a Buy. 8 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RVTY?
You can purchase shares of Revvity via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revvity shares.
-
What Is The Revvity Share Price Today?
Revvity was last trading at $111.83 per share. This represents the most recent stock quote for Revvity. Yesterday, Revvity closed at $111.91 per share.
-
How To Buy Revvity Stock Online?
In order to purchase Revvity stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
Sell
50
NUTX alert for Mar 15
Nutex Health [NUTX] is up 14.56% over the past day.
